These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2516611)

  • 1. Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis.
    Tomson CR; Channon SM; Ward MK; Laker MF
    Nephrol Dial Transplant; 1989; 4(9):792-9. PubMed ID: 2516611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma oxalate in patients receiving continuous ambulatory peritoneal dialysis.
    Tomson CR; Channon SM; Parkinson IS; Owen JP; Ward MK; Simpson JM; Laker MF
    Nephrol Dial Transplant; 1988; 3(3):295-9. PubMed ID: 3140104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine.
    Morgan SH; Maher ER; Purkiss P; Watts RW; Curtis JR
    Nephrol Dial Transplant; 1988; 3(1):28-32. PubMed ID: 3132636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxalate retention in chronic renal failure: tubular vs glomerular diseases.
    Tomson CR; Channon SM; Ward MK; Laker MF
    Clin Nephrol; 1989 Aug; 32(2):87-95. PubMed ID: 2788548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxalate clearance by haemodialysis--a comparison of seven dialysers.
    Franssen CF
    Nephrol Dial Transplant; 2005 Sep; 20(9):1916-21. PubMed ID: 15998647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD).
    Yamauchi A; Fujii M; Shirai D; Mikami H; Okada A; Imai E; Ando A; Orita Y; Kamada T
    Clin Nephrol; 1986 Apr; 25(4):181-5. PubMed ID: 3698351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.
    Elgstoen KB; Johnsen LF; Woldseth B; Morkrid L; Hartmann A
    Nephrol Dial Transplant; 2010 Jul; 25(7):2341-5. PubMed ID: 20167571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxalic acid concentration in serum measured by isotopic clearance technique. Experience in hyper- and normo-oxaluric subjects.
    Prenen JA; Mees EJ; Boer P; Endeman HJ; Ephraim KH
    Proc Eur Dial Transplant Assoc; 1979; 16():566-70. PubMed ID: 549000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
    Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
    Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.
    Ono K
    Clin Nephrol; 1986 Nov; 26(5):239-43. PubMed ID: 3802587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure.
    Watts RW; Veall N; Purkiss P
    Clin Sci (Lond); 1984 May; 66(5):591-7. PubMed ID: 6368103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diurnal variation in plasma oxalate concentration and oxalate clearance in calcium oxalate stone formers with special reference to the effect of oxalate loading].
    Kinoshita N
    Hinyokika Kiyo; 1987 Sep; 33(9):1331-41. PubMed ID: 3434488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Plasma oxalate concentration in calcium oxalate stone formers].
    Hoshina A
    Hinyokika Kiyo; 1984 Oct; 30(10):1405-15. PubMed ID: 6524552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma glycolate concentrations under conditions of dialysis].
    Balcke P; Schmidt P; Zazgornik J; Kopsa H; Haubenstock A
    Wien Klin Wochenschr; 1983 Sep; 95(18):656-8. PubMed ID: 6649652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary oxalosis in chronic renal insufficiency].
    Balcke P; Schmidt P; Zazgornik J; Kopsa H; Deutsch E
    Z Urol Nephrol; 1982 Jun; 75(6):409-14. PubMed ID: 7124142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
    Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine and its determinants in nondialyzed chronic kidney disease patients.
    Nerbass FB; Draibe SA; Feiten SF; Chiarello PG; Vannucchi H; Cuppari L
    J Am Diet Assoc; 2006 Feb; 106(2):267-70. PubMed ID: 16442876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria.
    Marangella M; Cosseddu D; Petrarulo M; Vitale C; Linari F
    Nephrol Dial Transplant; 1993; 8(12):1333-7. PubMed ID: 8159301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.